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Abstract
Background: Humanized mice (hu mice) are based on the transplantation of hematopoietic stem and progenitor
cells into immunodeficient mice and have become important pre-clinical models for biomedical research. However,
data about their hematopoiesis over time are scarce. We therefore characterized leukocyte reconstitution in NSG
mice, which were sublethally irradiated and transplanted with human cord blood-derived CD34+ cells at newborn
age, longitudinally in peripheral blood and, for more detailed analyses, cross-sectionally in peripheral blood, spleen
and bone marrow at different time points.
Results: Human cell chimerism and absolute human cell count decreased between week 16 and 24 in the peripheral
blood of hu mice, but were stable thereafter as assessed up to 32 weeks. Human cell chimerism in spleen and bone
marrow was maintained over time. Notably, human cell chimerism in peripheral blood and spleen as well as bone
marrow positively correlated with each other. Percentage of B cells decreased between week 16 and 24, whereas
percentage of T cells increased; subsequently, they levelled off with T cells clearly predominating at week 32. Natural
killer cells, monocytes and plasmacytoid dendritic cells (DCs) as well as CD1c + and CD141+ myeloid DCs were all
present in hu mice. Proliferative responses of splenic T cells to stimulation were preserved over time. Importantly, the
percentage of more primitive hematopoietic stem cells (HSCs) in bone marrow was maintained over time.
Conclusions: Overall, leukocyte reconstitution was maintained up to 32 weeks post-transplantation in our hu NSG model,
possibly explained by the maintenance of HSCs in the bone marrow. Notably, we observed great variation in multi-lineage
hematopoietic reconstitution in hu mice that needs to be taken into account for the experimental design with hu mice.
Keywords: Hematopoiesis, Hematopoietic stem cells, Cord blood stem cell transplantation, Humanized mice, NSG mice
Background
Humanized mice (hu mice) generated via the transplant-
ation of human hematopoietic stem and progenitor cells
(HSPCs), fetal tissues or mature immune cells into immu-
nodeficient mice serve as small animal models for bio-
medical research [1]. Immunodeficiency is a pre-requisite
for efficient engraftment. Various immunodeficient mouse
strains are in use for the generation of hu mice. They all
have in common a mutated Prkdc gene (encoding DNA-
dependent protein kinase, catalytic subunit) or a targeted
disruption in the Rag1/2 genes which result in a lack of
functional T and B cells; in most cases, the IL2 receptor
common gamma chain (IL2rg) is also disrupted, com-
promising the development of murine innate immune
cells including nature killer (NK) cells [2–4].
The efficiency of engraftment is also dependent on a
“do not eat me” signal triggered by the binding of CD47,
which is ubiquitously expressed, to the signal regulatory
protein alpha (SIRPα) receptor on phagocytic cells [5].
The mouse SIRPα allele on macrophages of Non-obese-
diabetic (NOD) mice efficiently recognizes the human
CD47 on engrafted cells and thus prevents their
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phagocytosis [6]. In contrast, the SIRPα allele of C57BL/6
mice does not bind to human CD47 and thus does not
trigger this inhibitory axis, resulting in phagocytosis of
xenotransplanted cells and lack of reconstitution of
human hematopoiesis; the SIRPα allele of BALB/c mice
moderately binds to human CD47, resulting in limited
graft efficiency [7].
Strains of immunodeficient IL2rgnull mice on a NOD
background that are commonly used by investigators in-
clude NOD.Cg-PrkdcscidIl2rgtm1Sug (abbreviated NOG)
[2, 8], NOD.Cg-PrkdcscidIl2rgtm1Wjll (NSG) [3, 9], and
NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) [10]. NOG
and NSG mice both have a mutated Prkdc gene, whereas
NRG mice have a targeted disruption in the Rag1 gene;
NOG mice have a cytoplasmic truncation, and NSG
mice a complete deletion of the IL2rg. Engraftment of
human hematopoietic stem cells (HSCs) derived from
umbilical cord blood is more efficient in NSG mice than
NOG mice [11], but similar between NSG and NRG
mice [12]. The difference in the overall engraftment be-
tween NOG and NSG mice is likely attributable to the
presence of the IL2rg extracellular domain in the NOG
mice [11]. Currently, the most widely used strain for
generating hu mice is the NSG mouse.
In NSG mice, human cell chimerism was shown to be
maintained up to 24 weeks post-transplantation; the
number of mice used, however, was only three, making
it difficult to draw any firm conclusions [9]. Only two
studies reported hematopoietic cell reconstitution be-
yond 24 weeks post-transplantation; these studies used
NRG mice [13] and BALB/c-Rag2nullIl2rgnull (BRG) mice
[14] transplanted at newborn age with cord blood-
derived cells. In NRG mice, lymphoid cells and mono-
cytes remained stable in the peripheral blood for ~1 year
[13], whereas in BRG mice, a decline of human cell chi-
merism from week 6 to week 40 in blood and bone mar-
row and after week 24 in spleen was noted [14]. Notably,
hematopoietic cell reconstitution, especially the develop-
ment of B and T cells, is dynamic, with B cells decreas-
ing and T cells increasing during the first 3 to 4 months
irrespective of the mouse strain [1, 13, 14].
The aim here was to assess whether leukocyte recon-
stitution in hu NSG mice is maintained beyond week 24
post-transplantation. We addressed this question by
monitoring human cell chimerism, absolute human cell
count and reconstitution of B and T cells longitudinally
between week 16 and 32 in peripheral blood. We also
did a more detailed analysis, including reconstitution of
other hematopoietic cell populations such as NK cells
and dendritic cells (DCs), cross-sectionally at week 16,
24, or 32 post-transplantation in peripheral blood, spleen
and bone marrow. Engraftment of HSPCs and more
primitive hematopoietic stem cells (HSCs) in bone mar-
row was also analyzed. We started our analyses at week
16 as leukocyte reconstitution in hu mice is, as
mentioned above, dynamic until this time point post-
transplantation. Our data support overall maintenance
of leukocyte reconstitution up to 32 weeks post-
transplantation in our hu NSG model, but also reveal
high inter-animal variation in leukocyte subset
reconstitution.
Methods
Humanized mice
Immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjll (NSG)
mice were obtained from The Jackson Laboratory or
Charles River Laboratories. For reconstitution, newborn
NSG mice were irradiated 1–2 days after birth with 1 Gy
and subsequently injected intrahepatically (i.p.) with
1.74 ± 0.57 x 105 (mean ± SD) CD34+ cells. CD34+ cells
were isolated from human cord blood with immuno-
magnetic beads (CD34 MicroBead Kit; Miltenyi Biotec)
with a purity of 92.8 ± 5.9% (n = 25) and cryopreserved
in FBS and 10% DMSO until use. Procurement of hu-
man cord blood was approved by the ethical committee
of the University of Zurich. Human cord blood was col-
lected with informed written consent of the parents. All
animal experiments were approved by the Cantonal Vet-
erinary Office.
In some cases, mice presented progressive alopecia in-
dicating graft versus host disease. Mice with alopecia
were not included into experiments respectively mice
showing symptoms of graft versus host disease during
the monitoring period were excluded from analyses.
Mice originating from the same litter are referred to as
a group of mice; a cohort of mice consisted of several
groups of mice.
Immunostaining and flow cytometry
Human cell chimerism and percentages of human cell
populations were determined in peripheral blood, spleen
and bone marrow at various time points. For absolute cells
counts, peripheral blood was collected into EDTA tubes
(BD Biosciences). White blood cell counts (WBC/ml)
were determined with a COULTER® Ac · T diff™ Analyzer
(Beckman Coulter) using 20 μl of peripheral blood diluted
in buffer according to the manufacturer’s instructions.
Otherwise, peripheral blood was collected from the tail
vein into FACS tubes containing FACS buffer (PBS con-
taining 2 mM EDTA, 2% FBS, 0.1% sodium azide), centri-
fuged and incubated with antibodies in FACS buffer for
20 min at room temperature (RT). Erythrocytes were lysed
with BD FACS Lysing Solution (BD Biosciences) for
10 min at RT. Cells were washed with PBS containing
2 mM EDTA, resuspended in FACS buffer and kept at 4 °C
until flow cytometric analysis.
Splenocytes were obtained by squeezing the spleens
through a 70 μm nylon mesh. Bone marrow cells were
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obtained by cutting both ends of the femur and tibia,
flushing the bone marrow with PBS containing 2% FBS
and 2 mM EDTA, and passing the cells through a 70 μm
nylon mesh. Erythrocytes in both spleen and bone mar-
row cell suspensions were lysed with ACK lysis buffer
(Lonza) and were cryopreserved until use.
Cryopreserved bone marrow and spleen cells were
thawed, counted and incubated with antibodies in FACS
buffer for 20 min at 4 °C. Cells were washed with FACS
buffer, fixed with 2% paraformaldehyde and kept at 4 °C
until flow cytometry. Control staining included all anti-
bodies except those against minor cell populations (e.g.,
NK cells and DCs). Mouse BD Fc Block™ was included
for staining of bone marrow cells for HSPCs; PE/Cy7
Mouse IgG1 κ Isotype Ctrl Antibody was used as control
for anti-CD141 PE-Cy7 antibody in staining of
splenocytes.
For measuring cell proliferation and activation upon
stimulation, splenocytes and human peripheral blood
mononuclear cells (PBMCs) were incubated with
Dynabeads® Human T-Activator CD3/CD28 (Life
Technologies) at a bead-to-cell ratio of 1:1 for 72 h.
Human PBMCs were isolated from buffy coats (local
blood donation center in Zurich) by Lymphoprep™
(Alere Technologies AS) density gradient centrifugation.
After removal of the beads, cells were incubated with
antibodies against cell surface antigens (CD45, CD3,
CD4, CD8, CD25) in FACS buffer for 20 min at 4 °C,
washed with FACS buffer, fixed/permeabilized with BD
Cytofix/Cytoperm™ (BD Biosciences) for 20 min at 4 °C,
washed with 1× BD Perm/Wash solution, incubated with
anti-Ki67 antibody in 1× BD Perm/Wash solution for
30 min at 4 °C, washed with 1× BD Perm/Wash solu-
tion, resuspended in FACS buffer and kept at 4 °C until
flow cytometry analysis.
Antibodies (all specific for human, unless otherwise in-
dicated) were purchased from BD Biosciences, BioLegend,
Beckman Coulter or Miltenyi Biotec (Additional file 1:
Table S1). Stained cells were acquired on a CyAn ADP
flow cytometer (Beckman Coulter) and flow cytometry
data were analyzed with FlowJo Version 7.2.5 or 10.0.8
(Tree Star). Doublets and cells with a low FSC/SSC profile
were gated out.
Immunoglobulin ELISA
Human IgM and IgG concentrations in plasma were de-
termined using Human IgM and IgG ELISA Kit (Bethyl
Laboratories), respectively, following the manufacturer’s
instructions.
Statistical analysis
For statistical analysis of longitudinal data between week
12 and 24 post-transplantation, we applied multilevel
mixed-effects linear regression models with a random-
intercept term at mice level, with a significance level of p
< 0.05 using Stata® SE version 14.0 (Stata Corporation,
College Station, TX). Paired t tests were used to compare
week 16/24 or week 24/32, with a significance level of p <
0.05 using GraphPad prism 6 (GraphPad Software, Inc).
For statistical analysis of cross-sectional flow cytome-
try and immunoglobulin production data, groups of dif-
ferentially aged mice were compared using one-way
analysis of variance (ANOVA) followed by Tukey post-
hoc test using GraphPad prism 6. Values in the text indi-
cate mean ± SD. Bars in graphs in Figs. 3, 4, 5, 6, 7, 8, 9,
10, 11 and Additional file 2: Figure S3 indicate mean
values. Paired t tests were used to compare the percent-
age of CD45+ cells between peripheral blood and spleen
or bone marrow. A significance level of p < 0.05 (* p <
0.05, ** p ≤ 0.01, *** p ≤ 0.001) was used for all tests.
For sample size calculations, we used Sattertwaite’s t
tests assuming unequal variances in order to provide an
estimation of the sample sizes needed to detect a decline
in the percentage of CD4+ T cells between 0 and 25%
for different power assumptions at a two-sided α-level of
0.05. Stata® version 13.1 was used for sample size
calculations.
Results
Human cell chimerism, absolute human cell count and
reconstitution of B and T cells in peripheral blood
As most studies using hu mice are performed between
week 12 and 24 weeks post-transplantation, we first
monitored human cell chimerism and reconstitution of
B and T cells in peripheral blood longitudinally every
four weeks between week 12 and 24 after transplantation
with cord blood-derived CD34+ cells in two groups of
hu mice. Overall, human cell chimerism, as determined
by the percentage of human CD45+ cells, showed inter-
and intra-animal variation, but was not significantly
declining over time (coefficient -0.8, 95% CI: -2.1 – 0.6,
p = 0.27) (Fig. 1a). In contrast, the percentages of B and
T cells changed over time, with a predominance of B
cells at week 12 and a steady decrease thereafter up to
week 24 post-transplantation (coefficient -4.7, 95% CI:
-5.6 – -3.9, p < 0.001) and vice versa a low percentage of
T cells at week 12 and subsequently a steady increase
(coefficient 4.4, 95% CI: 3.5 – 5.3, p < 0.001) (Fig. 1b).
Within the T cell population, the percentages of CD4+
and CD8+ T cells also changed over time (coefficient
1.8, 95% CI: 0.9–2.7 and -1.4, 95% CI: -2.2 – -0.7, p <
0.001 for both) in favor of CD4+ T cells (Fig. 1c). Thus,
the B and T cell compartment is dynamic with a signifi-
cant change of the ratio of B and T cells during the first
24 weeks post-transplantation.
To study hematopoietic cell reconstitution beyond
24 weeks post-transplantation, we monitored human cell
chimerism, absolute human cell count and reconstitution
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of B and T cells in peripheral blood longitudinally be-
tween week 16 and 32 after transplantation in several
groups of hu mice. Human cell chimerism, in percent
(Fig. 2a, left and Table 1) as well as absolute cell
numbers (Fig. 2a, right) slightly decreased between
week 16 and 24 (p = 0.046, paired t test), but was
stable between week 24 and 32. In contrast, lymphoid
cell subsets showed substantial changes between week
16 and 24: B cells decreased and T cells increased
(Fig. 2b). Since B and T cells are the two main lymphoid
cell populations, B and T cell percentages are largely in-
versely proportionate. After week 24, the percentages of
both subsets were stable. We also observed a dynamic pat-
tern for CD4+ and CD8+ T cells: CD4+ T cells increased
over time, predominantly between week 16 and 24,
whereas CD8+ T cells decreased between week 16 and 24
(Fig. 2c). Thus, human cell chimerism, absolute human
cell count and particularly reconstitution of B and T cells
in peripheral blood are dynamic up to week 24 and then
level off.
We also determined relative and absolute human cell
levels and reconstitution of B and T cells in peripheral
blood in several groups of hu NSG mice cross-sectionally
at week 16, 24, and 32. In essence, we obtained data simi-
lar to those from mice examined longitudinally (Fig. 3 and
Table 2). We present these data here since the more
detailed analyses, i.e., of additional hematopoietic cell
populations in peripheral blood and of the reconstitution
Fig. 1 Longitudinal analysis of human cell chimerism and B and T cells in peripheral blood between week 12 and 24 post-transplantation. Human
cell chimerism and percentages of B and T cells were assessed in peripheral blood longitudinally every four weeks between week 12 and 24
post-transplantation. Each symbol represents an individual mouse; data are derived from two groups of mice, which are indicated by different
symbols (open/closed) (n = 10; number of mice per group: 4–6); each group of mice was transplanted with different cord blood-derived cells.
a percentage of human cells (CD45+), b percentage of B cells (CD19+) and T cells (CD3+), c percentage of CD4+ and CD8+ cells within the T
cell population
Audigé et al. BMC Immunology  (2017) 18:28 Page 4 of 15
of leukocytes in organs (see below), require cross-
sectional analyses.
Reconstitution of natural killer cells, monocytes and
dendritic cells in peripheral blood
We detected NK cells in 35/36 (97%), monocytes in 36/
36 (100%), plasmacytoid DCs (pDCs) in 27/36 (75%),
CD1c +myeloid DCs (mDCs) in 35/36 (97%), and
CD141+ mDCs in 30/36 (83%) hu mice in the peripheral
blood (Fig. 4 and Table 3). The percentage of NK cells
remained stable over 32 weeks. Monocytes were less fre-
quent at week 24 and 32 than week 16. The DC com-
partment gave a mixed picture: pDCs were less frequent
at week 32 than week 16, CD1c +mDCs remained stable
Fig. 2 Longitudinal analysis of human cell chimerism, absolute human cell count and B and T cells in peripheral blood between week 16 and 32
post-transplantation. Human cell chimerism, absolute human cell count and percentages of B and T cells were assessed in peripheral blood longitudinally
between week 16 and 32 post-transplantation. Each symbol represents an individual mouse; data are derived from 6 groups of mice (indicated by different
colours) (n= 21; number of mice per group: 1–7); each group of mice was transplanted with different cord blood-derived cells. a: percentage and absolute
count of human cells (CD45+), b: percentage of B cells (CD19+) and T cells (CD3+), c: percentage of CD4+ and CD8+ cells within the T cell population
Table 1 Human cell chimerism and reconstitution of
lymphocytes in peripheral blood (longitudinal)
16 weeks 24 weeks 32 weeks
CD45+ 33.5 ± 19.7% 24.4 ± 15.3% 21.8 ± 12.9%
B cells 49.5 ± 22.2% 24.6 ± 22.5% 18.8 ± 18.2%
T cells 43.6 ± 22.8% 69.3 ± 23.8% 74.1 ± 21.0%
CD4 T cells 55.5 ± 13.8% 62.5 ± 15.6% 69.4 ± 9.2%
CD8 T cells 33.5 ± 11.0% 25.1 ± 8.8% 22.3 ± 7.2%
Percentages are given as mean ± SD; n = 21
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over time, and CD141c + DCs were more frequent at
week 32 than week 24.
Hematopoietic cell reconstitution in spleen
Human cell chimerism in the spleen was on average
>70% (Fig. 5a, left and Table 4) and thus much higher
than in the peripheral blood (Additional file 3: Figure
S2A, left); human cell chimerism in peripheral blood
and spleen positively correlated with each other (p =
0.039) (Additional file 3: Figure S2A, right). Human cell
chimerism in the spleen was similar between mice sacri-
ficed at week 16, 24, or 32 post-transplantation (Fig. 5a,
left). In contrast, we observed a time-dependent
Fig. 3 Cross-sectional analysis of human cell chimerism, absolute human cell count and B and T cells in peripheral blood at week 16, 24, or 32
post-transplantation. Human cell chimerism, absolute human cell count and percentages of B and T cells were assessed in peripheral blood cross-sectionally
at week 16, 24 or 32 post-transplantation. a percentage and absolute count of human cells (CD45+), b percentage of B cells (CD19+) and T cells (CD3+), c
percentage of CD4+ and CD8+ cells within the T cell population. A, left, B and C: each symbol represents an individual mouse; data are derived from
multiple groups of mice per time point (number of groups: 16 weeks: n= 9, 24 weeks: n= 7, 32 weeks: n= 4; number of mice per group: 3–11); each group
of mice was transplanted with cells derived from a different cord blood. A, right: each symbol represents an individual mouse; data are derived from two
(16 and 32 weeks) or three (24 weeks) different groups of mice, which are indicated by different symbols (open/closed); each group was transplanted with
cells derived from a different cord blood
Table 2 Human cell chimerism and reconstitution of lymphocytes
in peripheral blood (cross-sectional)
16 weeks 24 weeks 32 weeks
CD45+ 29.7 ± 16.9% 26.4 ± 15.0% 29.5 ± 18.3%
B cells 63.7 ± 16.5% 27.7 ± 18.7% 55.6 ± 15.5%
T cells 25.0 ± 13.7% 61.9 ± 20.4% 29.1 ± 13.7%
CD4 T cells 52.3 ± 14.3% 62.9 ± 13.1% 60.2 ± 12.8%
CD8 T cells 37.4 ± 10.5% 30.6 ± 11.3% 35.6 ± 12.1%
Percentages are given as mean ± SD; n = 51 (16 weeks), 38 (week 24), 21
(week 32)
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decrease of the absolute number of CD45+ cells (Fig. 5a,
right). The analyses of B and T cells in the spleen essen-
tially reflected the results obtained in the peripheral
blood: we observed the highest percentage of B cells at
week 16 and vice versa the lowest percentage of T cells
at that time point; these percentages levelled off between
week 24 and 32 (Fig. 5b and Table 4). Notably, CD4+
and CD8+ T cells showed a peak and nadir, respectively
at week 24 (Fig. 5c). Regarding NK cells, monocytes, and
DCs in spleen, there was a major difference to peripheral
blood: these cell populations were present in the spleens
of all hu mice analyzed and none of them declined over
time (Fig. 5d). In line with these data, the percentage of
total myeloid cells as defined by the CD33 marker was
similar between the mice irrespective of their age
(Additional file 2: Figure S3, left). Gating strategy for as-
sessment of myeloid cell reconstitution in spleen is
shown in Additional file 4: Figure S4A.
T cell differentiation and responsiveness in spleen
The differentiation profiles of CD4+ and CD8+ T cells
were very similar: naïve cells and central memory cells
within the memory cell population constituted the most
frequent cell populations over time (Fig. 6). All kinds of
differentiated T cells, including effector, transitional
memory and effector memory cells, were present in the
spleen. We observed a number of statistically significant
differences when comparing the percentages of all cell
subsets at the various time points, but without an obvious
pattern (Fig. 6). Gating strategy for the analysis of T cell
differentiation is shown in Additional file 5: Figure S5A.
Proliferation (Ki-67) and activation (CD25) of CD4+
and CD8+ T cells in spleen were similarly enhanced at all
three time points post-transplantation upon stimulation
with CD3/CD28 beads (Fig. 7). The proliferative response
of splenic T cells from humanized mice was lower than
that of human PBMCs, while their activation upon stimu-
lation was similar to that of human PBMCs (Fig. 7).
B cell maturation/differentiation in spleen
The majority of B cells at ≥16 weeks post-transplantation
were mature and the percentage of memory B cell
Fig. 4 Reconstitution of NK cells, monocytes and DCs in peripheral blood. Reconstitution of NK cells, monocytes and DCs was assessed in
peripheral blood of hu NSG mice at week 16, 24, or 32 post-transplantation. Gating strategy is shown in Additional file 7: Figure S1. Upper panel:
percentage of NK cells (NKp46+) and monocytes (CD14+), lower panel: percentage of pDCs (CD303+), CD1c +mDCs (CD1c+) and CD141+ mDCs
(CD141+). Each symbol represents an individual mouse; data are derived from two (16 and 24 weeks) or three (32 weeks) different groups of
mice, which are indicated by different colours; each group was transplanted with cells derived from a different cord blood
Table 3 Reconstitution of NK cells, monocytes and DCs in
peripheral blood
16 weeks 24 weeks 32 weeks
NK cells 3.10 ± 1.69% 2.28 ± 1.28% 1.99 ± 1.22%
Monocytes 10.5 ± 3.64% 3.83 ± 2.68% 6.44 ± 3.95%
pDCs 1.30 ± 0.60% 0.59 ± 1.05% 0.45 ± 0.50%
CD1c +mDCs 1.69 ± 1.06% 1.11 ± 1.00% 1.06 ± 0.81%
CD141+ mDCs 0.57 ± 0.36% 0.06 ± 0.07% 1.01 ± 1.14%
Percentages are given as mean ± SD; n = 12 (16 weeks), 10 (week 24), 14
(week 32)
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increased over time (Fig. 8 and Table 4). Gating strategy
for analysis of B cell maturation/differentiation is shown
in Additional file 5: Figure S5B.
Immunoglobulin production
IgM was consistently detected in all mice analyzed at a
level of >20 μg/ml (Fig. 9). In contrast, IgG levels were
<1 μg/ml in most animals. In five mice, IgG levels were
>1 μg/ml and showed a high variability. IgM or IgG
levels were similar between week 16, 24, and 32 post-
transplantation.
Leukocyte reconstitution and engraftment of HSPCs/HSCs
in bone marrow
Human cell chimerism (percentage of human CD45+
cells) in bone marrow was on average >64% irrespective
of the time point post-transplantation when the mice
were sacrificed (Fig. 10, upper panel, left and Table 5)
and positively correlated with the one in the peripheral
blood (p = 0.0008) (Additional file 3: Figure S2A, right).
Furthermore, the percentage of CD34+ cells in the bone
marrow significantly correlated with the percentage of
human CD45+ cells in the peripheral blood (r = 0.359, p =
0.047; data not shown).
Fig. 5 Leukocyte reconstitution in spleen. Human cell chimerism, absolute human cell count and reconstitution of lymphocytes, monocytes, and
DCs were assessed in spleen at week 16, 24, or 32 post-transplantation. a percentage and absolute count of human cells (CD45+), b percentage
of B cells (CD19+), and T cells (CD3+), c percentage of CD4+ and CD8+ T cells within the T cell population, d percentage of NK cells (NKp46+)
and monocytes (CD14+), pDCs (CD303+), CD1c +mDCs (CD1c+) and CD141+ mDCs (CD141+). Each symbol represents an individual mouse; data
are derived from two (16 and 32 weeks) or three (24 weeks) different groups of mice, which are indicated by different symbols (open/closed);
each group was transplanted with cells derived from a different cord blood
Audigé et al. BMC Immunology  (2017) 18:28 Page 8 of 15
Within the same animals, human cell chimerism and
percentages of B cells, monocytes and DCs (Fig. 10 and
Table 5) were significantly higher in bone marrow than
in the peripheral blood (Additional file 3: Figure S2B,
left). B cells constituted the cell population with the
highest percentage in the bone marrow (Fig. 10, upper
panel, middle and Table 5). At week 32, monocytes and
mDCs showed a decrease in percentage as compared to
the previous time points analyzed (Fig. 10, upper panel,
right, and lower panel). However, the percentage of
total myeloid cells in the bone marrow was similar
between the different time points post-transplantation
(Additional file 2: Figure S3, right). Gating strategy for as-
sessment of myeloid cell reconstitution in bone marrow is
shown in Additional file 4: Figure S4B. The discrepancy of
decreasing monocytes and mDCs while overall myeloid
cells remained stable over time might be explained by the
presence of a variety of other myeloid cells not analyzed.
We observed a decrease of the total CD34+ cells, in-
cluding stem and progenitor cells, between week 16 and
Table 4 Hematopoietic cell reconstitution in spleen
16 weeks 24 weeks 32 weeks
CD45+ 83.3 ± 9.93% 71.0 ± 18.2% 72.9 ± 20.1%
B cells 78.8 ± 4.42% 53.7 ± 20.5% 43.7 ± 14.7%
Mature 63.8 ± 3.63% 69.4 ± 12.3% 61.7 ± 11.8%
Memory 0.53 ± 0.26% 3.12 ± 2.24% 4.86 ± 1.61%
T cells 9.27 ± 2.14% 32.5 ± 18.0% 37.9 ± 19.0%
CD4 T cells 51.6 ± 8.89% 65.7 ± 12.0% 46.9 ± 8.77%
Memory 52.7 ± 9.87% 77.1 ± 14.0% 54.7 ± 26.4%
CD8 T cells 37.8 ± 8.75% 25.4 ± 19.2% 58.4 ± 32.3%
Memory 24.4 ± 4.71% 59.1 ± 22.8% 34.4 ± 30.8%
NK cells 5.85 ± 1.46% 7.61 ± 1.34% 8.74 ± 1.13%
Monocytes 1.94 ± 1.42% 0.73 ± 0.36% 1.71 ± 0.97%
pDCs 6.79 ± 1.92% 9.71 ± 1.97% 9.83 ± 1.28%
CD1c +mDCs 0.64 ± 0.32% 0.71 ± 0.25% 0.83 ± 0.37%
CD141+ mDCs 0.05 ± 0.02% 0.05 ± 0.06% 0.07 ± 0.01%
Percentages are given as mean ± SD; n = 6 (16 weeks), 8 (week 24), 8 (week 32)
Fig. 6 Differentiation of T cells in spleen. CD4+ (a) and CD8+ (b) T cells in spleen were analyzed for differentiation. Gating strategy is shown in
Additional file 5: Figure S5A. T cell differentiation was defined as follows: naïve (N) = CD45RO-CCR7+, memory (M) = CD45RO+, terminal effector
(TE) CD45RO-CCR7-, central memory (CM) = CD45RO+CCR7+, transitional memory (TM) = CD45RO+CCR7-CD27+, effector memory (EM) = CD45RO+CCR7-
CD27-. Symbols: see Fig. 5
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24 (Fig. 11, left and Table 5). The percentages of the
more primitive cells, as defined by CD34 + CD38- or
CD34 + CD90+, were very low (Fig. 11, middle and
right), but, importantly, remained in a similar range
during the entire observation period. Gating strategy for
analysis of engraftment of HSPCs/HSCs in bone marrow
is shown in Additional file 6: Figure S6.
Impact of inter-animal variation on design of experimen-
tal studies using hu mice
Multi-lineage hematopoietic reconstitution showed great
inter-animal variation in our hu NSG mice. This is of
great importance for the design of experimental studies
using hu mice. An example is the estimation of the num-
ber of mice required to monitor preservation of CD4+ T
Fig. 7 Functional characterization of T cells in spleen. Splenocytes and human PBMCs from two donors were stimulated with Dynabeads® Human
T-Activator CD3/CD28 for 72 h and analyzed for proliferation (percentage of Ki67+ cells; a) and activation (percentage of CD25+ cells; b) of CD4
(left) and CD8 (right) T cells. Data are presented as fold-change relative to unstimulated cells. For each PBMC control, the mean fold-change from two
experiments is shown. Symbols: see Fig. 5
Fig. 8 Maturation/differentiation of B cells in spleen. B cells in spleen were analyzed for maturation. Gating strategy is shown in Additional file 5:
Figure S5B. B cell subpopulations were defined as follows: Pro/Pre/Imm/Tra (pro-B, pre-B, immature, transitional B cells) = CD38hiCD24hi,
mature = CD38intCD24int, memory = CD38loCD24hi
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cells upon anti-HIV treatment in HIV-infected hu mice.
Infection of hu mice with HIV strains, such as the
CXCR4-tropic strain NL4-3, usually results in progressive
CD4+ T cell depletion similarly to HIV-infected individ-
uals. As shown for a group of HIV-infected mice, the aver-
age percentage of CD4+ T cells decreases by 13% during
the first two months post-infection (p.i.) (Fig. 12a). In un-
infected hu NSG mice, the average percentage of CD4+ T
cells increases by 12% between week 16 and 24 post-
transplantation (Fig. 2c, left). If the hypothesis is that the
compound/drug preserves CD4+ T cells completely upon
HIV infection, a total number of 40 mice is required for a
statistical power of 0.8 (Fig. 12b).
Discussion
Data on long-term multi-lineage hematopoiesis in hu
mice are rather scarce. For future studies, detailed
characterization is highly desirable, and thus, we filled
this gap by examining multi-lineage hematopoiesis of hu
NSG mice over time. The hu mice were generated using
cord blood-derived CD34+ cells transplanted shortly
after birth. We found that 1) human cell chimerism de-
creased in peripheral blood up to week 24, but thereafter
levelled off until week 32; chimerism remained stable in
spleen and bone marrow; absolute numbers decreased in
peripheral blood up to week 24, and in spleen over the
entire observation time; 2) lymphocyte cell subsets
Fig. 9 Production of immunoglobulins. Human IgM and IgG concentrations were determined in plasma (of the same mice as those data for
which are shown in Figs. 5, 6, 7, 8). Symbols: see Fig. 5
Fig. 10 Leukocyte reconstitution in bone marrow. Human cell chimerism and percentages of B cells, monocytes and DCs were assessed in bone
marrow (of the same mice as those data for which data are shown in Fig. 4) at week 16, 24, or 32 post-transplantation. Upper panel: percentage
of human (CD45+) cells, B cells (CD19+), and monocytes (CD14+), lower panel: percentage of pDCs (CD303+), CD1c +mDCs (CD1c+) and CD141+ mDCs
(CD141+). Symbols: see Fig. 4
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showed a dynamic picture with an initial decline of the
percentage of B cells between week 16 and 24 and level-
ling off after week 24; the percentage of T cells behaved
in an opposite manner with a clear predominance of T
cells over B cells after week 24; 3) in the B cell compart-
ment, we observed an increase of memory cells over
time, which however did not translate into a progressive
increase of IgG production; 4) we found a preserved
proliferation response of T cells to stimulation over time;
5) other immune cells studied, i.e., NK cells, monocytes
and DCs, were present over the entire observation
period; 6) the level of multi-lineage hematopoietic re-
constitution greatly varied between animals; and 7) the
percentage of HSCs in bone marrow was stable over
time and likely the basis for the long-term multi-lineage
hematopoiesis observed. These data validate the hu
mouse model for its use in biomedical research. The ra-
ther large variability needs to be taken into account
when working with hu mice.
We report here that human cell chimerism was main-
tained over 32 weeks post-transplantation in hu NSG
mice, extending previous data showing the preservation
of multi-lineage hematopoiesis up to 24 weeks post-
transplantation in NSG mice [9]. Consistent with our
data, hu NRG mice transplanted i.p. with cord blood-
derived CD34+ cells showed reconstitution of B and T
cells and monocytes in peripheral blood for ~1 year [13].
In contrast, BRG mice transplanted i.p. or intravenously
at newborn age with cord blood-derived CD34+ cells
and T cell-depleted CD34- “support” cells showed a
progressive decline of human cell chimerism [14]. The
preserved multi-lineage hematopoiesis we observed in
the NSG model as well as in the NRG model might be
explained by the NOD background of the mice and its
ability to promote the “do not eat me signal”. As men-
tioned above, BRG mice have a BALB/c background,
which has a SIRPα allele poorly recognizing the human
CD47 [7].
Blood human cell chimerism showed intra-animal
variation over time. The reason for these fluctuations is
unknown, but might relate to the bleeding method.
Non-uniform warming of mice prior to tail bleeding can
result in alterations in blood parameters, particularly of
total white blood cells [15].
The predominance of B cells over T cells early after
transplantation of HSPCs and its reversal later at/up to
12 to 16 weeks post-transplantation is a well-known
phenomenon in hu mice [1]. We do not see this
phenomenon in adult patients following allogeneic stem
cell transplantation – both B and T cells show a pro-
tracted immune reconstitution with cell recovery in the
2nd year after transplantation [16]. Our longitudinal data
showing the dynamic of B and T cell development
clearly speak in favor of a preserved multi-lineage
hematopoiesis and that the human immune system in
hu mice needs a rather long time to reach a plateau. In
the NRG model, peripheral T cells similarly increased
over time with subsequent levelling off at a high per-
centage at ~5 months lasting for more than a year; B
cells showed the opposite pattern [13]. The same holds
Table 5 Hematopoietic cell reconstitution and engraftment of
HSPCs in bone marrow
16 weeks 24 weeks 32 weeks
CD45+ 70.9 ± 10.9% 63.9 ± 18.4% 76.8 ± 6.44%
B cells 63.2 ± 13.5% 45.1 ± 26.4% 80.7 ± 7.72%
Monocytes 13.4 ± 4.55% 9.85 ± 5.47% 6.64 ± 3.16%
DCs 10.3 ± 4.69% 11.7 ± 4.32% 5.98 ± 2.29%
CD34+ 10.8 ± 2.70% 3.98 ± 2.57% 7.60 ± 1.82%
CD38- 1.26 ± 0.42% 0.84 ± 0.22% 0.84 ± 0.46%
CD90+ 0.09 ± 0.05% 0.07 ± 0.04% 0.07 ± 0.05%
Percentages are given as mean ± SD; n = 12 (16 weeks), 10 (week 24), 9
(week 32)
Fig. 11 Engraftment of HSPCs/HSCs in bone marrow. Bone marrow of hu mice (same as those data for which are shown in Fig. 4) was analyzed
at week 16, 24, or 32 post-transplantation for the percentages of total HSPCs (CD34+) among human CD45+ cells (left) and of more primitive cells
(CD38- or CD90+; middle and right) among human CD45+ cells. Gating strategy is shown in Additional file 6: Figure S6. Symbols: see Fig. 4
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true for hu BRG mice, at least for the time frame re-
ported, i.e., up to week 24 after transplantation [14].
The longitudinal and cross-sectional data of the re-
constitution of B and T cells do not fully correspond
to each other. We explain the discrepancy by the sub-
stantial variability in the reconstitution of T cells and
associated decline in B cells between groups of hu
mice, or even individual mice. Let’s remind that a
group of mice is defined by the transplantation with
the same donor blood.
The majority of B cells in the spleen in our model
were mature over the entire observation period. Previous
studies with hu mice on different mouse backgrounds
reported a predominantly immature B cell phenotype
[14, 17, 18]. Possible explanations for this discrepancy
include differences in the mouse background, the age of
the mice at the time point of analysis, and/or the
markers used to determine maturation. Virtually all
splenic mature B cells were in a naïve state 16 weeks
post-transplantation consistent with data from Watanabe
et al. [18]. We noted a subtle but statistically significant
progressive increase of memory B cells over time in the
spleen. The B cell compartment consistently produced hu-
man IgM in the hu NSG mice, but only rarely human IgG,
indicating lack of Ig class switching. The IgM levels in the
hu mice were in a similar range as in men based on the
reference values provided by the manufacturer. The data
concerning Ig class switching in hu mice are controversial.
IgG could not be detected at week 12 post-transplantation
in one study [17] and only in about half of animals in an-
other study [19]. In contrast, Traggiai et al. detected IgG,
albeit to various degrees, in older hu mice [4] and Lang et
al. showed increasing levels of IgG between week 16 and
24 post-transplantation [14], indicating class switching.
Again, we explain these divergent results by the different
mouse strains and/or protocols used for generating the hu
mice. Differences in the hygiene in the animal care facil-
ities might be another factor to be considered.
The memory phenotype was strongly represented in
the CD4+ as well as in the CD8+ T cell compartment in
the spleen. In the NRG model discussed above, the
memory CD4+ and CD8+ T cells, i.e., CD45RO+ cells,
continually increased over time and were the predomin-
ant T cell subset at later time points in the peripheral
blood [13]. Notably, they lost the CD28 cell surface
marker pointing to a senescent state [13]. While we have
not formally assessed senescence, stimulation-induced
proliferation and activation did not differ at the various
time points post-transplantation analyzed.
Crucially, other kinds of immune cells analyzed, includ-
ing NK cells, monocytes, and DCs, were also present in
the hu NSG mice over the entire observation period.
Overall, their percentages at week 24 post-transplantation
(when multi-lineage hematopoiesis levels off) were within
the range of normal percentages of these cell types in
human peripheral blood (NK cells: 1 − 6%, monocytes: 2 –
12%, DCs: 0.3 – 0.9% of leukocytes in human peripheral
blood). In contrast, the percentages of B and T cells are
much higher in our model and most other hu mouse
models than in human peripheral blood (B cells: 1 – 7%, T
cells: 7 – 24% of leukocytes in human peripheral blood).
In human peripheral blood, myeloid cells predominate
over lymphocytes (53 – 86 vs 14 – 47% of leukocytes, re-
spectively), whereas in hu mice, human myeloid cells
rarely exceed 5–10% of leukocytes [1]. Indeed, the
percentage of myeloid (CD33+) cells in the spleens of our
hu mice was on average 4% at 16, 24 and 32 weeks post-
transplantation. This percentage was, however, much
higher in the bone marrow, which can be explained by the
fact that CD33 is also expressed on myeloid progenitors.
An exception to the low percentage of myeloid cells in hu
mice are the more recently developed strains MITRG and
Fig. 12 Example for estimated sample sizes required for animal
experimentation. a: percentage of CD4+ T cells (of CD45 + CD3+
cells) in hu NSG mice was determined before (baseline) and at week
8 after infection with the R4-tropic HIV strain NL4-3. b: figure depicts
total sample sizes required to detect a decline in the percentage of
CD4+ T cells between 0% and 25% for different power assumptions.
Calculations were based on a mean increase in the percentage of
CD4+ T cells of 11.7% (SD: 12.4%) between week 16 and week
24 post-transplantation
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MISTRG, in which the percentage of these cells closely re-
sembles that in humans [20].
Sustained multi-lineage hematopoiesis requires the
maintenance of HSPCs in the bone marrow, at the best,
of the most primitive cells. We found that the percent-
age of CD34+ HSPCs was lower at later time points but
overall well preserved. Furthermore, the more primitive
cells (CD34 + CD38- or CD34 + CD90+) were preserved
over the entire period. We believe that this preservation
contributes to the superior multi-lineage hematopoiesis
in hu NSG mice as compared to other hu mouse
models. Indeed, BRG mice transplanted with fetal liver-
derived sorted CD34 + CD38- cells experienced a
decrease of the percentage of CD34 + CD38- cells
already at 6 weeks of age [21].
Multi-lineage hematopoietic reconstitution varied
widely between animals in our hu NSG mouse model.
This variation needs to be considered when designing
experiments with hu mice, i.e., we need to integrate the
dynamic nature of the lymphoid system into our power
calculation as illustrated by the example for testing a
compound’s protective activity against HIV-associated
CD4+ T cell loss. Other estimations of sample sizes can
be made based on our data sets. Thus, our study
provides an important basis for the design of future ex-
perimental work using hu mice.
Notably, the NSG mouse is the most widely used
strain for humanization. Novel strains are constantly be-
ing developed, mainly with knock-ins of human cyto-
kines, or even knock-out of distinct genes for better
engraftment. For example, derivatives of the NSG strain
include NSG-SGM3 (or NSGS) mice, which express
human stem cell factor, granulocyte-macrophage colony-
stimulating factor, and interleukin-3 [22], and NSGW41
mice, which have a loss-of-function KIT receptor [23].
Human cell development in NSGS mice is skewed to-
ward regulatory T cells, highlighting the importance of
adequate spatiotemporal expression of human cytokines
in xenotransplantation models [22]. NSGW41 mice
support improved human erythropoiesis and platelet for-
mation compared with irradiated NSG mice [24]. A
characterization as we did here for NSG mice is neces-
sary for each novel mouse model introduced into
biomedical research.
Conclusions
In summary, NSG mice transplanted with cord blood-
derived CD34+ cells present preserved multi-lineage
hematopoiesis up to 32 weeks. The considerable
inter-animal variation and dynamic developmental
pattern of various cell subtypes represent major chal-
lenges for the experimental design of experiments
using hu mice.
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between peripheral blood and spleen or bone marrow. Paired t test (left)
and correlation (right) analyses were performed of human cell chimerism
in peripheral blood and spleen (A) or bone marrow (B) (TIF 9278 kb)
Additional file 4: Figure S4. Gating strategy for assessment of myeloid
cell reconstitution in spleen and bone marrow. Representative examples
for the assessment of myeloid cell (CD33+) reconstitution in spleen (A)
and bone marrow (B) are shown. (TIF 30248 kb)
Additional file 5: Figure S5. Gating strategy for assessment of T cell
differentiation and B cell maturation/differentiation in spleen.
Representative examples for the assessment of T cell differentiation (A)
and B cell maturation/differentiation (B) are shown. (TIF 85813 kb)
Additional file 6: Figure S6. Gating strategy for assessment of
engraftment of HSPCs in bone marrow. A representative example for the
assessment of engraftment of HSPCs in bone marrow is shown.
Percentages of cell populations were determined as follows: Total HSPCs:
%CD34+ cells (of CD45+ cells), more primitive cells: %CD38- or CD90+
cells (of CD45 + CD34+ or CD45+ cells). (TIF 5264 kb)
Additional file 7: Figure S1. Gating strategy for assessment of human
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representative example for the assessment of human cell chimerism and
leukocyte reconstitution is shown. A: chimerism: %CD45+ cells (of live
cells), B cells: %CD19+ cells (of CD45+ cells), monocytes: %CD14+ (of
CD45+ cells), pDCs: %CD303+ cells (of CD45+ cells), CD1c +mDCs:
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